For busy readers
- Australian digital health startup Eucalyptus is being acquired by US-based Hims & Hers for up to $1.15B.
- The deal gives the buyer global expansion across Australia, Europe, Japan, and Canada.
- Signals a new consolidation phase in global telehealth and digital healthcare platforms.
A billion-dollar exit from Australia’s startup ecosystem
Australia’s tech ecosystem doesn’t produce unicorn exits every week.
But when it does, the signal tends to be global.
Sydney-based telehealth startup Eucalyptus is being acquired by US consumer health giant Hims & Hers in a deal valued at up to $1.15 billion, marking one of the largest recent exits for an Australian tech startup.
The acquisition includes:
- About $240M upfront cash
- Additional deferred and performance-based payments through 2029
The goal: build a global consumer healthcare platform spanning multiple continents.
From startup to global health platform
Founded in 2019, Eucalyptus built a digital health model focused on preventive and personalized care delivered online.
Its portfolio includes:
- Pilot → men’s health
- Juniper → weight-loss and women’s health
- Kin → fertility and reproductive care
- Dermatology and chronic care services
The company has already served 775,000+ customers globally, with operations across Australia, UK, Germany, Canada, and Japan.
Annual revenue run-rate reportedly exceeds $450M, with strong growth in recent years.
That scale made it an attractive acquisition target.
Why Hims & Hers bought it
For Hims & Hers, this isn’t just an acquisition — it’s a global expansion strategy.
The US company wants to:
- Expand beyond North America
- Build localized healthcare platforms
- Combine pharmacy + telehealth + preventative care
Eucalyptus provides:
- Existing international infrastructure
- Regulatory expertise across regions
- A multi-brand consumer health model
With the acquisition, Hims & Hers gains deeper presence in:
- Australia
- Japan
- UK
- Germany
- Canada
This effectively turns the company into a global digital health operator overnight.
Why this deal matters beyond Australia
This isn’t just a local startup exit.
It signals something bigger: global telehealth consolidation has begun.
Digital health boomed during the pandemic.
But now the industry is entering its next phase:
- Fewer standalone startups
- More cross-border acquisitions
- Larger integrated platforms
Analysts see this deal as a shift toward unified global consumer health ecosystems rather than fragmented regional players.
In simple terms:
health tech is moving from startup phase → infrastructure phase.
A rare employee and founder windfall
The acquisition is also notable for its internal payouts.
Reports suggest:
- Over 100 employees will receive significant share payouts
- Average payouts around $420K
- CEO Tim Doyle could earn up to $163M depending on milestones
For Australia’s startup ecosystem, this creates:
- New angel investors
- Experienced operators with exit experience
- Fresh capital recycling into new startups
Exactly how strong ecosystems evolve.
The strategic timing
The acquisition comes as global healthcare shifts toward:
- Subscription-based treatment
- Preventive care
- Digital-first consultations
- Personalized treatment models
Telehealth is no longer just about video calls.
It’s becoming a full-stack healthcare delivery system.
Platforms that combine:
- Diagnostics
- Prescriptions
- coaching
- long-term care
are now more valuable than single-feature apps.
Eucalyptus built that model early —
and global players noticed.
What this means for startups globally
The message from this deal is clear:
1. Health tech consolidation has started
Large platforms will acquire regional leaders.
2. Preventive care is becoming a major tech category
Weight loss, fertility, dermatology, longevity — all moving online.
3. Australia is producing globally relevant startups
Not just local SaaS — but exportable digital infrastructure.
Final signal
For years, telehealth was treated like a temporary pandemic boom.
This deal proves it’s becoming permanent infrastructure.
A startup founded just a few years ago has now become a billion-dollar global acquisition target.
And if consolidation continues,
more regional health tech startups could soon follow the same path.
